BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21134979)

  • 21. New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
    Fathi AT; Karp JE
    Curr Oncol Rep; 2009 Sep; 11(5):346-52. PubMed ID: 19679009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
    Walsby E; Lazenby M; Pepper C; Burnett AK
    Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
    Drummond CJ; Finlay GJ; Broome L; Marshall ES; Richardson E; Baguley BC
    Invest New Drugs; 2011 Oct; 29(5):1102-10. PubMed ID: 20567995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
    Ferguson DM; Jacobson BA; Jay-Dixon J; Patel MR; Kratzke RA; Raza A
    Anticancer Res; 2015 Oct; 35(10):5211-7. PubMed ID: 26408679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
    Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
    Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
    Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
    Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cells.
    Hikita K; Yamakage Y; Okunaga H; Motoyama Y; Matsuyama H; Matsuoka K; Murata T; Nakayoshi T; Oda A; Kato K; Tanaka H; Asao N; Dan S; Kaneda N
    Bioorg Med Chem; 2021 Jan; 30():115904. PubMed ID: 33341500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.
    Bjørnstad R; Aesoy R; Bruserud Ø; Brenner AK; Giraud F; Dowling TH; Gausdal G; Moreau P; Døskeland SO; Anizon F; Herfindal L
    Mol Cancer Ther; 2019 Mar; 18(3):567-578. PubMed ID: 30679386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
    Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
    Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting acute myeloid leukemia with TP53-independent vosaroxin.
    Benton CB; Ravandi F
    Future Oncol; 2017 Jan; 13(2):125-133. PubMed ID: 27615555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3.
    Guo H; Lin SY; Ren WX; Lei Q; Chen ZC; Zhang L; Li QB
    Curr Med Sci; 2018 Feb; 38(1):35-42. PubMed ID: 30074149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
    Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
    Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation.
    He PX; Zhang J; Che YS; He QJ; Chen Y; Ding J
    Acta Pharmacol Sin; 2014 Dec; 35(12):1546-55. PubMed ID: 25468822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study.
    Nemr MTM; AboulMagd AM
    Bioorg Chem; 2020 Oct; 103():104134. PubMed ID: 32750610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.
    Hawtin RE; Stockett DE; Wong OK; Lundin C; Helleday T; Fox JA
    Oncotarget; 2010 Nov; 1(7):606-619. PubMed ID: 21317456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Effect of
    Labbozzetta M; Poma P; Occhipinti C; Sajeva M; Notarbartolo M
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
    Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
    Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
    Guo L; Liu X; Nishikawa K; Plunkett W
    Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HU-331 is a catalytic inhibitor of topoisomerase IIα.
    Regal KM; Mercer SL; Deweese JE
    Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.